

# Saskia C Ting

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7858618/publications.pdf>

Version: 2024-02-01

33  
papers

589  
citations

686830

13  
h-index

610482

24  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimisation of the Chicken Chorioallantoic Membrane Assay in Uveal Melanoma Research. <i>Pharmaceutics</i> , 2022, 14, 13.	2.0	19
2	OTHR-34. Identifying mechanisms of microglia-tumor cell interactions in retinoblastoma. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	0.6	0
3	Increased Expression of AKT3 in Neuroendocrine Differentiated Prostate Cancer Cells Alters the Response Towards Anti-Androgen Treatment. <i>Cancers</i> , 2021, 13, 578.	1.7	6
4	Increased longevity due to sexual activity in mole-rats is associated with transcriptional changes in the HPA stress axis. <i>ELife</i> , 2021, 10, .	2.8	17
5	Feasibility of Proton Beam Therapy as a Rescue Therapy in Heavily Pre-Treated Retinoblastoma Eyes. <i>Cancers</i> , 2021, 13, 1862.	1.7	7
6	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	1.7	7
7	Electrochemotherapy with Bleomycin Enhances Radiosensitivity of Uveal Melanomas: First In Vitro Results in 3D Cultures of Primary Uveal Melanoma Cell Lines. <i>Cancers</i> , 2021, 13, 3086.	1.7	9
8	A qPCR based method for molecular subtype classification of urinary bladder cancer stromal gene expressions show higher prognostic values than intrinsic tumor genes. <i>International Journal of Cancer</i> , 2021, , .	2.3	6
9	Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. <i>Scientific Reports</i> , 2020, 10, 16533.	1.6	12
10	Bone metastasis of retinoblastoma five years after primary treatment. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100834.	0.4	5
11	ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 10-16.	0.9	7
12	Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 236-247.e6.	1.0	5
13	New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation. <i>PLoS ONE</i> , 2019, 14, e0226199.	1.1	11
14	Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 145-153.e5.	0.9	10
15	Title is missing!. , 2019, 14, e0226199.		0
16	Title is missing!. , 2019, 14, e0226199.		0
17	Title is missing!. , 2019, 14, e0226199.		0
18	Title is missing!. , 2019, 14, e0226199.		0

#	ARTICLE	IF	CITATIONS
19	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	1.1	61
20	Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism. <i>European Journal of Endocrinology</i> , 2017, 177, 243-250.	1.9	17
21	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. <i>Oncology Research and Treatment</i> , 2017, 40, 435-439.	0.8	7
22	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 54-64.	0.5	62
23	NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. <i>Oncotarget</i> , 2017, 8, 42613-42620.	0.8	69
24	Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. <i>Oncotarget</i> , 2017, 8, 45898-45917.	0.8	12
25	Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. <i>Endocrine</i> , 2016, 54, 733-741.	1.1	41
26	Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis. <i>Oncotarget</i> , 2015, 6, 24690-24698.	0.8	15
27	Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. <i>Journal of Cancer</i> , 2014, 5, 646-654.	1.2	27
28	Activation of Angiogenesis Differs Strongly Between Pulmonary Carcinoids and Neuroendocrine Carinomas and Is Crucial for Carcinoid Tumourgenesis. <i>Journal of Cancer</i> , 2014, 5, 465-471.	1.2	22
29	Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study. <i>Modern Pathology</i> , 2014, 27, 1632-1640.	2.9	71
30	ERCC1, MLH1, MSH2, MSH6, and $\beta$ -Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2013, 14, 558-567.e3.	1.1	38
31	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. <i>European Journal of Cancer</i> , 2013, 49, 3076-3082.	1.3	26
32	Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC): An interim analysis of the CEBIFOX trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14502-e14502.	0.8	0
33	Long term results after intraocular surgery in treated retinoblastoma eyes. <i>Ocular Oncology and Pathology</i> , 0, , .	0.5	0